Savara Inc SVRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Savara Announces New Employment Inducement Grant
-
Savara Announces Chief Financial and Administrative Officer Transition
-
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
-
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
-
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
-
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
-
Savara Reports First Quarter Financial Results and Provides Business Update
-
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Trading Information
- Previous Close Price
- $5.74
- Day Range
- $5.60–5.81
- 52-Week Range
- $2.25–7.01
- Bid/Ask
- $5.64 / $5.75
- Shares Outstanding
- 204.93M
- Market Cap
- $1.17B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 70
- Website
- https://www.savarapharma.com
Valuation
|
Metric
|
SVRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.61 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SVRA
|
|---|---|
Quick Ratio | 13.12 |
Current Ratio | 13.47 |
Interest Coverage | — |
Quick Ratio
SVRA
Profitability
|
Metric
|
SVRA
|
|---|---|
Return on Assets (Normalized) | −55.36% |
Return on Equity (Normalized) | −72.32% |
Return on Invested Capital (Normalized) | −62.30% |
Return on Assets
SVRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&?@vhC? | LOCK|jbDJ? | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%&>d@B^ | LOCK|hT&S | $69B | |||
| argenx SE ADR
ARGX
| LOCK|N^^xYk | LOCK|W@ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|l$Chbg^ | LOCK|^Nhk | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Q&&>^M | LOCK|cb | $36B | |||
| Moderna Inc
MRNA
| LOCK|X@>sy@@ | LOCK|CWq | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|dkKLQWjF | LOCK|qS@hJ | $25B | |||
| Incyte Corp
INCY
| LOCK|X$t>Q@Y | LOCK|cqv | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%<LgFk | LOCK|Nh | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&Qwcr@ | LOCK|@vj | $16B |
United States